In 2022, the Global Chronic Pain Management Market generated revenue of US$ 93.31 billion in 2022 and is estimated to witness a rise in revenue growth of US$ 168.68 billion by 2031, growing at a CAGR of 6.8% during the forecast period from 2023 to 2031.
The chronic pain management market on a global scale is experiencing a remarkable increase in revenue. This growth is primarily attributed to the increasing prevalence of chronic diseases. Additionally, factors like an aging population, greater patient awareness and education, advancements in pain management devices, and favorable reimbursement conditions in developed nations are contributing to the expansion of the market.
A Request of this Sample Report Here- https://www.astuteanalytica.com/request-sample/chronic-pain-management-market
Chronic pain is a debilitating condition that has a significant impact on the lives of millions of adults worldwide. It is estimated that approximately 20% of the global population experiences chronic pain. The burden of chronic pain is increasing globally, with 1.9 billion people affected by recurrent tension-type headaches, which is the most common chronic symptom. Research indicates that the prevalence of chronic pain in adults is 33% in middle-income and low-income countries and even higher at 56% in the elderly population. In China, the prevalence rate of chronic pain exceeds 30%. This growing prevalence of chronic pain is leading to an increased demand for chronic pain management products, thereby driving market growth.
A New Trend: Digital Care for Chronic Pain Management
Digital care solutions provide a non-pharmacological approach to pain management, reducing reliance on opioids and minimizing the risk of addiction. The demand for digital care has increased during the COVID-19 pandemic, particularly due to the rising cases of chronic pain. According to statistics published by PubMed in April 2022, patients with chronic pain in the United States and Canada experienced a significant increase in pain during the pandemic, leading to an increased demand for telehealth services.
According to a study published in the Journal of Pain Research, participants in a digital exercise therapy program were 42% less likely to initiate opioid use compared to those in traditional physical therapy (PT). The study also revealed that after 12 months, participants in the digital program had 25% fewer opioid prescriptions compared to traditional PT patients. This highlights the potential of digital care solutions in reducing opioid reliance and promoting alternative pain management approaches.
Traditional pain treatments can be costly for employers. According to the Business Group on Health, over 75% of employers consider musculoskeletal conditions as one of their top three cost drivers. Opioid treatments, in particular, can be expensive when considering hospitalizations, addiction, rehabilitation, and the impact on an individual’s personal life. In contrast, digital care solutions can help reduce costs by minimizing the need for costly prescriptions and surgeries. By offering digital care, employers not only save on expensive treatment plans but also promote employee well-being and satisfaction, positively impacting workplace culture and employee engagement.
Neuropathic Pain Controlled Over 33.2% of Market Revenue Share
In 2022, the neuropathic pain segment accounted for 33.2% of the global chronic pain management market. This growth is driven by the increasing incidence of neuropathic pain, which affects approximately 7-10% of the global population. The segment’s expansion is fueled by the rising prevalence of diseases such as diabetic neuropathy and post-herpetic neuralgia, greater awareness of neuropathic pain, and the availability of more effective treatment options.
Diabetic neuropathy and post-herpetic neuralgia, which are associated with diabetes and herpes zoster respectively, are the primary neuropathic conditions. Diabetic neuropathy is a common cause of chronic pain in individuals with diabetes, with an estimated 50% of people with diabetes developing this condition at some point.
Our analysis indicates that tricyclic antidepressants (TCAs) have been found to be effective in treating painful neuropathy, nerve injury pain, post-herpetic neuralgia, central postpartum pain, and general pain management. Additionally, several clinical trials have been conducted to evaluate the efficacy of new therapeutic approaches for neuropathic pain.
North America Dominated the global Chronic Pain Management Market
North America emerged as the dominant region in the pain management market, with the United States contributing the highest revenue share. The market in North America is projected to witness further growth due to factors such as the increasing demand for long-term pain management among the aging population and advancements in the field of pain management.
Furthermore, based on PubMed data from 2022, there is an increasing prevalence of chronic pain among Americans. Approximately one in five individuals in the region experience chronic pain each year. This highlights the growing demand for effective chronic pain management throughout the country, as chronic pain has become one of the most common chronic health conditions in the United States.
In response, the United States allocates significant resources to address the issue of chronic pain. According to a 2022 report on the chronic pain management market, the US healthcare system spends over $100 billion annually on pain medications, including both over-the-counter and prescription drugs such as opioids and non-opioid medications. Further, around US$ 300 billion was directed towards complementary and alternative therapies like physiotherapy, acupuncture, and cognitive behavioral therapy in the same year.
For The Full Report, Please Follow This Link- https://www.astuteanalytica.com/industry-report/chronic-pain-management-market
Furthermore, the American Society of Regional Anesthesia and Pain Medicine (ASRA) has highlighted that long-term opioid therapy and the use of steroids in interventional pain procedures may lead to immune suppression. This is significant because it weakens the body’s ability to fight off various viral infections. As a result, all of these factors are expected to contribute to an increased demand for chronic pain management throughout the projected period.
List of Prominent Companies
- Eli Lilly and Company
- GlaxoSmithKline plc.
- Pfizer Inc.
- Abbott Laboratories
- Novartis AG
- Johnson & Johnson
- AstraZeneca plc.
- Bristol-Myers Squibb Company
- Dickinson and Company
- Sanofi S.A.
- Other prominent players
The global chronic pain management market segmentation focuses on Product, Application, and Region.
- Electrical Stimulators
- Radiofrequency Ablation (RFA)
- Analgesic Infusion Pumps
- Neuropathic Pain
- Facial & Migraine
- Musculoskeletal Disorder
- North America
- The U.S.
- Western Europe
- The UK
- Rest of Western Europe
- Eastern Europe
- Rest of Eastern Europe
- Western Europe
- Asia Pacific
- South Korea
- Australia & New Zealand
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of MEA
- South America
- Rest of South America
Get a Free Sample Report Here- https://www.astuteanalytica.com/request-sample/chronic-pain-management-market
About Astute Analytica
Astute Analytica is a global analytics and advisory company that has built a solid reputation in a short period, thanks to the tangible outcomes we have delivered to our clients. We pride ourselves in generating unparalleled, in-depth and uncannily accurate estimates and projections for our very demanding clients spread across different verticals. We have a long list of satisfied and repeat clients from a wide spectrum including technology, healthcare, chemicals, semiconductors, FMCG, and many more. These happy customers come to us from all across the Globe. They are able to make well-calibrated decisions and leverage highly lucrative opportunities while surmounting the fierce challenges all because we analyze for them the complex business environment, segment-wise existing and emerging possibilities, technology formations, growth estimates, and even the strategic choices available. In short, a complete package. All this is possible because we have a highly qualified, competent, and experienced team of professionals comprising of business analysts, economists, consultants, and technology experts. In our list of priorities, you-our patron come at the top. You can be sure of best cost-effective, value-added package from us, should you decide to engage with us.
𝐆𝐞𝐭 𝐢𝐧 𝐭𝐨𝐮𝐜𝐡 𝐰𝐢𝐭𝐡 𝐮𝐬
𝐏𝐡𝐨𝐧𝐞 𝐧𝐮𝐦𝐛𝐞𝐫: +𝟏𝟖𝟖𝟖𝟒𝟐𝟗𝟔𝟕𝟓𝟕
𝐕𝐢𝐬𝐢𝐭 𝐨𝐮𝐫 𝐰𝐞𝐛𝐬𝐢𝐭𝐞: https://www.astuteanalytica.com/